Alzamend Neuro, Inc. (ALZN) - 10-Q Summary
Business Context and Reporting Period
Company: Alzamend Neuro, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended January 31, 2026
Business Overview: A clinical-stage biopharmaceutical company developing novel treatments for Alzheimer's disease, bipolar disorder, major depressive disorder, and PTSD. The company has two primary product candidates: AL001 (a lithium-based ionic cocrystal) and ALZN002 (a cell-based therapeutic vaccine). The company has generated no product revenue to date and relies on equity and debt financing.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2026 | Nine Months Ended Jan 31, 2026 | Balance Sheet (Jan 31, 2026) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,198,991) | $(5,902,433) | N/A |
| Operating Expenses | $(2,197,654) | $(5,895,964) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $2,713,139 |
| Working Capital | N/A | N/A | $1,841,954 |
| Total Assets | N/A | N/A | $4,041,833 |
| Total Liabilities | N/A | N/A | $1,857,328 |
| Stockholders' Equity | N/A | N/A | $2,184,505 |
| Accumulated Deficit | N/A | N/A | $(64,437,694) |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by 112% for the three months ended Jan 31, 2026, compared to the prior year period, driven primarily by a 189% increase in Research and Development (R&D) expenses and a 56% increase in General and Administrative (G&A) expenses.
- R&D Expenses: R&D expenses rose to $1.28 million (3-month) and $3.20 million (9-month) due to clinical trial fees for the AL001 Phase IIB study conducted with Massachusetts General Hospital.
- G&A Expenses: G&A expenses increased significantly due to higher legal fees ($295k in Q3 2026 vs $35k in Q3 2025) related to litigation against a former Contract Research Organization (CRO) regarding the termination of the ALZN002 clinical trial.
- Capital Structure: The company completed the conversion of Series B and Series C Convertible Preferred Stock into common stock during the period. Series A, B, and C preferred stock were eliminated via Certificates of Elimination.
- Stock Splits: The company executed a 1-for-10 reverse stock split in July 2024 and a 1-for-9 reverse stock split in May 2025. All share data presented reflects these splits.
Outlook, Risks, and Management Commentary
- Liquidity and Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for at least one year from the filing date. Cash on hand ($2.7 million) is insufficient to fund planned operations through the next 12 months. The company plans to raise additional capital through public/private equity or debt financings.
- Clinical Progress:
- AL001: Completed the clinical portion of the Phase II study in healthy human subjects in November 2025; topline data is expected in Q1 2026. The company is preparing for further trials in patients with Alzheimer's, BD, MDD, and PTSD.
- ALZN002: The Phase I/IIA trial was terminated due to the CRO (Biorasi) ending the contract. The company is seeking a replacement CRO.
- Financing Activities: During the nine months ended Jan 31, 2026, the company raised $4.0 million through the issuance of Series C Convertible Preferred Stock. Subsequent to the period end (March 6, 2026), the company entered into an At-the-Market (ATM) offering agreement to sell up to $3.0 million of common stock.
- Internal Controls: The company disclosed a material weakness in internal control over financial reporting due to insufficient accounting resources, which restricts the ability to review manual journal entries and account reconciliations. Remediation is ongoing.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $2.7 million cash balance against the projected burn rate of approximately $2.2 million per quarter to assess immediate funding needs.
- Legal Litigation: Confirm the status and potential financial impact of the litigation against the former CRO (Biorasi) regarding the ALZN002 trial termination.
- ATM Offering: Monitor the execution of the new $3.0 million At-the-Market offering announced in March 2026 and its potential dilutive effect on existing shareholders.
- Clinical Data: Await the topline data for the AL001 Phase II study in healthy subjects expected in Q1 2026, which is critical for advancing the program.
- Internal Controls: Track the remediation progress of the material weakness in financial reporting controls to ensure future financial statement reliability.